Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05898646 |
Recruitment Status :
Recruiting
First Posted : June 12, 2023
Last Update Posted : January 17, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
AL Amyloidosis | Procedure: Bone Marrow Aspiration Biological: Daratumumab Procedure: Echocardiography Other: Questionnaire Administration Procedure: X-Ray Imaging Procedure: Biospecimen Collection | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 96 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Phase II Study Evaluating Maintenance in Light Chain Amyloidosis (EMILIA) |
Actual Study Start Date : | July 17, 2023 |
Estimated Primary Completion Date : | November 1, 2024 |
Estimated Study Completion Date : | November 1, 2024 |
Arm | Intervention/treatment |
---|---|
Experimental: Arm I (6 cycles of daratumumab)
Patients receive daratumumab subcutaneously (SC) on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity for up to 6 cycles on study. Patients also undergo x-ray imaging at screening and bone marrow biopsy and blood sample collection throughout the study. Patients with cardiac involvement also undergo echocardiography throughout the trial.
|
Procedure: Bone Marrow Aspiration
Undergo bone marrow aspiration Biological: Daratumumab Given SC
Other Names:
Procedure: Echocardiography Undergo echocardiography
Other Name: EC Other: Questionnaire Administration Ancillary studies Procedure: X-Ray Imaging Undergo x-ray imaging
Other Names:
Procedure: Biospecimen Collection Undergo blood sample collection
Other Names:
|
Active Comparator: Arm II (18 cycles of daratumumab)
Patients receive daratumumab SC on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity for up to 18 cycles on study. Patients also undergo x-ray imaging at screening and bone marrow biopsy and blood sample collection throughout the study. Patients with cardiac involvement also undergo echocardiography throughout the trial.
|
Procedure: Bone Marrow Aspiration
Undergo bone marrow aspiration Biological: Daratumumab Given SC
Other Names:
Procedure: Echocardiography Undergo echocardiography
Other Name: EC Other: Questionnaire Administration Ancillary studies Procedure: X-Ray Imaging Undergo x-ray imaging
Other Names:
Procedure: Biospecimen Collection Undergo blood sample collection
Other Names:
|
- Event free survival [ Time Frame: From registration up to 36 months ]The point estimate for the hazard ratio and corresponding one-sided 85% confidence interval will be generated with a stratified Cox regression (using the trial stratification factors) that has treatment arm as an exploratory variable.
- Hematological response [ Time Frame: At the end of maintenance treatment ]A success is defined as a complete response (CR), very good partial response (VGPR) and partial response (PR). Hematological response must be maintained or improved during maintenance. Loss of level of hematological response (i.e., CR to VGPR/PR/progressive disease [PD], VGPR to PR/PD or PR to PD) will be considered a failure. The rate of hematological response will be defined as the number of successes divided by the total number of evaluable patients. Exact binomial 95% confidence intervals for the true success proportions will be calculated. All responses will be assessed and compared to values at diagnosis (and not at trial registration).
- Minimal residual disease (MRD) negativity rate [ Time Frame: Up to 36 months ]Will be estimated by the number of successes divided by the total number of evaluable patients who consented for MRD assessment. Exact binomial 95% confidence intervals for the true success proportions will be calculated.
- Organ response rates [ Time Frame: At 6, 12, 18, 24, and 36 months from registration ]Cardiac, renal, and hepatic response rates will be evaluated separately. The rate of organ response will be estimated by the number of successes divided by the total number of evaluable patients. Exact binomial 95% confidence intervals for the true success proportions will be calculated. All responses will be assessed and compared to values at diagnosis (and not at trial registration)
- Overall survival (OS) [ Time Frame: Time from registration to death from any cause, assessed up to 5 years ]Median OS will be estimated using the Kaplan-Meier method. Patients who do not experience death while on study will be censored at the last known date alive. The median OS and corresponding 95% confidence interval will be reported by arm (6 vs. 18 cycles of daratumumab maintenance).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age >= 18 years
- Histological confirmation of AL amyloidosis with adequate typing (mass spectrometry, immunohistochemistry, immunofluorescence, immunogold)
-
AL amyloidosis with organ disease requiring therapy
- NOTE: Disease requiring therapy is referred to the time of diagnosis. There are no limitations in baseline measurable disease parameters
-
Patients must have monoclonal protein studies (serum free light chain assay, serum immunofixation or serum MASS-FIX) obtained at time of diagnosis before induction therapy initiated and available for review to be enrolled.
- NOTE: Patients are allowed to participate in this study if urine electrophoresis immunofixation study was not done at time of diagnosis or cannot be obtained
- Patients must have completed 6 cycles of daratumumab (Dara)-CyBorD-based induction treatment =< 84 days prior to registration
-
Patients must have achieved a hematological complete response (CR) (irrespective of organ response achievement) or hematological very good partial response (VGPR) (irrespective of organ response achievement) or hematological low-difference in involved and uninvolved free light chain (dFLC) partial response (PR) (irrespective of organ response achievement) or hematological PR with at least one organ response after receiving Dara-CyBorD-based induction.
- NOTE: Patients with baseline dFLC < 5 mg/dL, must have achieved hematological CR, or dFLC < 1 mg/dL or achieved organ response prior to randomization
-
Patients in whom bortezomib and/or cyclophosphamide were omitted from induction due to toxicity concerns or adverse effects are allowed. Patients must receive at least daratumumab and dexamethasone at induction to qualify for the study
- NOTE: Dexamethasone use does not need to be carried to end of induction for eligibility consideration
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, 2 or 3
- Hemoglobin >= 8.0 g/dL (obtained =< 28 days prior to registration)
- Absolute neutrophil count (ANC) >= 1000/mm^3 (obtained =< 28 days prior to registration)
- Platelet count >= 50,000/mm^3 (obtained =< 28 days prior to registration)
-
Negative pregnancy test done =< 7 days prior to registration, for persons of childbearing potential only.
- NOTE: If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
-
Provide written informed consent
- NOTE: Informed consent required =< 90 days prior registration
- Ability to complete questionnaire(s) by themselves or with assistance
- Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Exclusion Criteria:
-
Any of the following because this study involves an agent that has possible genotoxic, mutagenic and teratogenic effects:
- Pregnant persons
- Nursing persons
- Persons of childbearing potential (and persons able to father a child) who are unwilling to employ adequate contraception
- Received >1 cycle of daratumumab maintenance after end of induction therapy and prior to registration
-
Multiple myeloma at time of diagnosis as defined by any of the following:
- Hypercalcemia: Serum calcium > 1 mg/dL higher than upper limit of normal or > 11 mg/dL
- Renal insufficiency: Creatinine clearance < 40 mL per min or serum creatinine > 2 mg/dL attributed to high circulating light chains (i.e. cast nephropathy) or hypercalcemia
- Anemia: Hemoglobin > 2 g/dL below lower limit of normal, or < 10 g/dL, attributed to high marrow myeloma infiltration
- Bone lesions: >= 1 osteolytic lesion on skeletal x-ray, computed tomography (CT), or positron emission tomography (PET)-CT (bone imaging is not mandatory but based on clinical suspicion)
- Clonal bone marrow plasma cells >= 60%
- > 1 focal lesion on magnetic resonance imaging (MRI) (MRI is not mandatory but based on clinical suspicion)
-
If bone imaging (CT, MRI, PET-CT) was not done at time of diagnosis it is not needed to be performed at registration to rule out bone disease
- >= 40% BMPCs irrespective of the above
- The study will allow patients with involved: uninvolved serum-free light chain (sFLC) ratio >= 100 if this is the only criteria that defines amyloidosis if all the above criteria are not met
- Seropositive for hepatitis B (defined by a positive test for hepatitis B surface antigen [HBsAg]). Note: Subjects with resolved infection (i.e., subjects who are HBsAg negative but positive for antibodies to hepatitis B core antigen [anti-HBc] and/or antibodies to hepatitis B surface antigen [anti-HBs]) must be screened using real-time polymerase chain reaction (PCR) measurement of hepatitis B virus (HBV) deoxyribonucleic acid (DNA) levels. Those who are PCR positive will be excluded. EXCEPTION: Subjects with serologic findings suggestive of HBV vaccination (anti-HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by PCR
-
Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy.
- NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial
-
Uncontrolled intercurrent illness including, but not limited to:
- Ongoing or active infection
- Unstable angina pectoris
- Psychiatric illness/social situations that would limit compliance with study requirements
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05898646
Contact: Clinical Trials Referral Office | 855-776-0015 | mayocliniccancerstudies@mayo.edu |
United States, Arizona | |
Mayo Clinic in Arizona | Recruiting |
Scottsdale, Arizona, United States, 85259 | |
Contact: Clincal Trials Referral Office 855-776-0015 mayocliniccancerstudies@mayo.edu | |
Principal Investigator: Rafael Fonseca, M.D. | |
United States, Florida | |
Mayo Clinic in Florida | Not yet recruiting |
Jacksonville, Florida, United States, 32224-9980 | |
Contact: Clinical Trials Referral Office 855-776-0015 mayocliniccancerstudies@mayo.edu | |
Principal Investigator: Taimur Sher, M.D. | |
United States, Minnesota | |
Mayo Clinic in Rochester | Recruiting |
Rochester, Minnesota, United States, 55905 | |
Contact: Clinical Trials Referral Office 855-776-0015 mayocliniccancerstudies@mayo.edu | |
Principal Investigator: Eli Muchtar, M.D. |
Principal Investigator: | Eli Muchtar, M.D. | Mayo Clinic in Rochester |
Responsible Party: | Mayo Clinic |
ClinicalTrials.gov Identifier: | NCT05898646 |
Other Study ID Numbers: |
MC220802 NCI-2023-03819 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ) 22-011048 ( Other Identifier: Mayo Clinic Institutional Review Board ) MC220802 ( Other Identifier: Mayo Clinic ) |
First Posted: | June 12, 2023 Key Record Dates |
Last Update Posted: | January 17, 2024 |
Last Verified: | January 2024 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Immunoglobulin Light-chain Amyloidosis Amyloidosis Proteostasis Deficiencies Metabolic Diseases Neoplasms, Plasma Cell Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders |
Immunoproliferative Disorders Immune System Diseases Paraproteinemias Daratumumab Antibodies, Monoclonal Antineoplastic Agents Immunologic Factors Physiological Effects of Drugs |